FLUOR-OP

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FLUOR-OP (FLUOR-OP).

How it works

Fluorometholone is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammatory responses.

What the body does with it

Metabolism	Fluorometholone is metabolized primarily in the liver via CYP3A4-mediated hydroxylation.
Excretion	Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with the remainder as metabolites (glucuronide conjugates) via urine; fecal elimination is minimal (<5%).
Half-life	Terminal elimination half-life is 3-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Protein binding	Approximately 10-20% bound to plasma proteins, primarily albumin; low binding reduces risk of drug interactions.
Volume of Distribution	0.15-0.25 L/kg, suggesting distribution primarily into extracellular fluid; low Vd reflects limited tissue penetration.
Bioavailability	Topical ophthalmic: Systemic bioavailability is <1% after ocular administration; topical dermatologic: Minimal systemic absorption (<5%) through intact skin.
Onset of Action	Ophthalmic (topical): 30-60 minutes for peak intraocular pressure reduction; topical dermatologic: 24-48 hours for antiviral effect; systemic absorption negligible with topical use.
Duration of Action	Ophthalmic: Duration of intraocular pressure reduction is 6-12 hours following instillation; requires multiple daily dosing (e.g., 3-4 times daily). For dermatologic use, antiviral effect persists with continued application.

Classification & Brands

Dosing & administration

2 drops of 0.1% solution into the affected eye(s) every 15 minutes for 4 doses, then every 30 minutes for 2 doses, then every 1-2 hours for 24-48 hours, then tapering over 1-2 weeks; alternatively, 0.5 cm ribbon of 0.05% ointment into the conjunctival sac 4-6 times daily.

Dosage form	SUSPENSION/DROPS
Renal impairment	No dose adjustment required for topical ophthalmic use; minimal systemic absorption.
Liver impairment	No dose adjustment required for topical ophthalmic use; minimal systemic absorption.
Pediatric use	Children ≥2 years: same as adult dosing; safety and efficacy in children <2 years not established.
Geriatric use	No specific dose adjustment; use same as adult dosing with monitoring for ocular adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FLUOR-OP (FLUOR-OP).

Breastfeeding	Contraindicated in breastfeeding. Fluorouracil is excreted into breast milk; M/P ratio not established. Risk of severe adverse effects in nursing infant (e.g., bone marrow suppression, gastrointestinal toxicity). Discontinue nursing or drug.
Teratogenic Risk	FDA Pregnancy Category X. Contraindicated in pregnancy. Fluorouracil is teratogenic in animals; fetal malformations (cleft palate, skeletal defects) reported. Risk of fetal harm outweighs any potential benefit. Use effective contraception during treatment.

Warnings & precautions

■ FDA Black Box Warning

Corticosteroids may increase intraocular pressure (IOP) in susceptible individuals, leading to glaucoma and optic nerve damage. Long-term use may suppress host immune responses and increase risk of secondary ocular infections. Prolonged use may also cause cataract formation.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to fluorometholone or any component of the formulation. Active viral (e.g., epithelial herpes simplex keratitis, vaccinia, varicella), fungal, or untreated bacterial ocular infections.

Clinical Precautions

Precautions

Monitor intraocular pressure regularly if used for 10 days or longer. Use with caution in patients with glaucoma, corneal thinning, or history of herpes simplex keratitis. Prolonged use may lead to fungal superinfection. Not for injection or oral use.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

FLUOR-OP

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FLUOR-OP (FLUOR-OP).

How it works

What the body does with it

Metabolism	Fluorometholone is metabolized primarily in the liver via CYP3A4-mediated hydroxylation.
Excretion	Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with the remainder as metabolites (glucuronide conjugates) via urine; fecal elimination is minimal (<5%).
Half-life	Terminal elimination half-life is 3-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Protein binding	Approximately 10-20% bound to plasma proteins, primarily albumin; low binding reduces risk of drug interactions.
Volume of Distribution	0.15-0.25 L/kg, suggesting distribution primarily into extracellular fluid; low Vd reflects limited tissue penetration.
Bioavailability	Topical ophthalmic: Systemic bioavailability is <1% after ocular administration; topical dermatologic: Minimal systemic absorption (<5%) through intact skin.
Onset of Action	Ophthalmic (topical): 30-60 minutes for peak intraocular pressure reduction; topical dermatologic: 24-48 hours for antiviral effect; systemic absorption negligible with topical use.
Duration of Action	Ophthalmic: Duration of intraocular pressure reduction is 6-12 hours following instillation; requires multiple daily dosing (e.g., 3-4 times daily). For dermatologic use, antiviral effect persists with continued application.

Classification & Brands

Dosing & administration

Dosage form	SUSPENSION/DROPS
Renal impairment	No dose adjustment required for topical ophthalmic use; minimal systemic absorption.
Liver impairment	No dose adjustment required for topical ophthalmic use; minimal systemic absorption.
Pediatric use	Children ≥2 years: same as adult dosing; safety and efficacy in children <2 years not established.
Geriatric use	No specific dose adjustment; use same as adult dosing with monitoring for ocular adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FLUOR-OP (FLUOR-OP).

Breastfeeding	Contraindicated in breastfeeding. Fluorouracil is excreted into breast milk; M/P ratio not established. Risk of severe adverse effects in nursing infant (e.g., bone marrow suppression, gastrointestinal toxicity). Discontinue nursing or drug.
Teratogenic Risk	FDA Pregnancy Category X. Contraindicated in pregnancy. Fluorouracil is teratogenic in animals; fetal malformations (cleft palate, skeletal defects) reported. Risk of fetal harm outweighs any potential benefit. Use effective contraception during treatment.